SETBP1 Antisense Oligonucleotides for Targeted Expression Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new approaches to treat SETBP1-associated diseases such as Schinzel-Giedion Syndrome and SETBP1-associated cancer, as current treatments are symptom-based and there is no known cure, and increased SETBP1 expression is linked to severe symptoms and neoplastic tumors.
Innovation Solution
The use of antisense oligonucleotides (ASOs) that are complementary to the SETBP1 nucleic acid sequence to inhibit SETBP1 expression, reducing protein levels and treating or preventing associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If antisense oligonucleotides are used to inhibit SETBP1 expression, then SETBP1 protein levels are reduced, but the complexity of the treatment approach increases
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to SETBP1 mRNA to prevent translation into protein. These ASOs act as mediators between the therapeutic goal (reducing SETBP1 protein) and the molecular target (mRNA), enabling selective inhibition without directly interacting with the protein itself.
Solution Approach 2:
The patent replaces traditional protein-targeting approaches (which would require complex small molecules or antibodies to reach intracellular targets) with nucleic acid-based therapy. This substitution leverages the cell's natural RNA interference and degradation pathways, simplifying the delivery mechanism while achieving the same therapeutic effect of reducing SETBP1 protein levels.
2Ease of operation
If current symptom-based treatments are used for SETBP1-associated diseases, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent employs preliminary action by targeting the mRNA transcript before it is translated into protein. By inhibiting translation at the mRNA level, the therapy prevents the formation of harmful SETBP1 proteins before they can exert their pathogenic effects, thereby addressing the root cause rather than merely treating symptoms after they manifest.
Solution Approach 2:
The patent extracts and targets the specific mRNA sequence encoding SETBP1 for inhibition. By isolating and targeting only the disease-causing SETBP1 transcripts (including mutant variants), the therapy achieves selective suppression of harmful protein production while leaving other cellular functions intact, thereby improving therapeutic effectiveness without requiring complex multi-target approaches.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ASOs effectively reduce SETBP1 expression, offering potential therapeutic benefits for Schinzel-Giedion Syndrome and SETBP1-associated cancer by decreasing protein levels and mitigating disease symptoms.
Implementation Method 1
antisense oligonucleotides (ASOs) that are complementary to the SETBP1 nucleic acid sequence
Data Source
AI summary
Described herein are reagents, products, methods, and uses for modulating SETBP1 expression, and uses thereof, such as for inhibiting SETBP1 expression in a cell, and for the treatment of SETBP1-associated diseases, such as Schinzel-Giedion Syndrome and SETBP1-associated cancer. The products include antisense oligonucleotides, such as modified antisense oligonucleotides, that target a region of the SETBP1 gene.